Therapeutic Goods Act 1989
Approval under section 42DF for use of restricted representations by
Molnlycke Health Care Pty Ltd
I, Rowena Love, as a delegate of the Secretary to the Department of Health and Aged Care, on receipt of an application from Molnlycke Health Care Pty Ltd, have approved under section 42DF of the Therapeutic Goods Act 1989, the restricted representations described in paragraph (A), for use in advertisements for the product identified in paragraph (B), when the statements identified in paragraph (C) are prominently displayed or communicated[1] in advertisements in which the restricted representations are used.
(A)
- Mepilex Ag is intended to be used on infected wounds or wounds at risk of infection with low to moderate amounts of wound fluid, such as:
- leg and foot ulcers
- pressure injuries
- partial-thickness burns
(B)
- Mepilex Ag - Wound-nonadherent dressing, absorbent, antimicrobial (ARTG 154420)
(C)
- Mepilex Transfer Ag should be used under the supervision of a qualified Healthcare Professional.
- If you are concerned about your wound, please contact your Healthcare Professional together, (the Representations).
Dated this 16th day of September 24
Signed electronically
Rowena Love
Delegate of the Secretary to the Department of Health and Aged Care
Advertising and Compliance Education and Policy Section
Regulatory Compliance Branch
[1] prominently displayed or communicated, in relation to a statement in an advertisement, means:
(a) either:
(i) for a visual statement—easily read from a reasonable viewing distance for the particular media type in the context in which the advertisement is intended to be viewed; or
(ii) for a spoken statement—able to be clearly heard and understood; and
(b) repeated as often as necessary to be noticed by a viewer or listener